Serum levels of insulin-like growth factor-I, IGF-binding protein 1 and 3, and insulin and endometrial cancer risk
2003

Insulin and Endometrial Cancer Risk

Sample size: 680 publication 10 minutes Evidence: moderate

Author Information

Author(s): Weiderpass E, Brismar K, Bellocco R, Vainio H, Kaaks R

Primary Institution: International Agency for Research on Cancer

Hypothesis

What is the relationship between serum levels of insulin-like growth factor-I, IGF-binding proteins, insulin, and the risk of endometrial cancer?

Conclusion

The study found no overall association between endometrial cancer risk and serum levels of IGF-1, IGFBP-1, IGFBP-3, and insulin.

Supporting Evidence

  • Obesity is associated with a 2-to-5-fold increase in endometrial cancer risk.
  • Insulin resistance and type II diabetes are established risk factors for endometrial cancer.
  • Women with elevated fasting serum levels of C-peptide have an increased risk of endometrial cancer.

Takeaway

This study looked at whether certain hormones in the blood could affect the risk of getting endometrial cancer, and it found that they don't seem to be related.

Methodology

A population-based case-control study was conducted with women aged 50-74 years, assessing serum levels of fasting insulin, IGF-I, IGFBP-1, and IGFBP-3.

Potential Biases

Possible selection bias due to differences in blood collection methods and non-participation rates.

Limitations

The study may have selection bias and potential confounding factors related to hormone levels.

Participant Demographics

Women aged 50-74 years from 12 Swedish counties, with no prior hysterectomy or history of cancer.

Statistical Information

P-Value

0.0430

Confidence Interval

95% CI

Statistical Significance

p<0.05

Digital Object Identifier (DOI)

10.1038/sj.bjc.6601312

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication